
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD
WATCH TIME: 5 minutes "Seeing CT1812’s impact across multiple biomarkers, not just one, is very encouraging—it reinforces the potential for real clinical benefit in Alzheimer treatment." The SHINE study (NCT03507790) is a double-blind, placebo- …